T-1

REFERENCIAS BIBLIOGRÁFICAS

  1. Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
  2. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, et al. All- transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992;80:2176-81.
  3. Fenaux P, Le Deley MC, Castaigne S. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-9.
  4. Asou N , Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukaemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 1998;16:78-85.
  5. Shen Z, Chen G, Ni J, Li X, Xiong S, Qiu Q, et al. Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood 1997;89:3354-60.
  6. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
  7. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
  8. Klaassen C D. Heavy metals and heavy-metal antagonists. En: Hardman JG, Gilman AG, Limbird LE, eds. The Pharmacological Basis of Therapeutics, New York: McGraw-Hill; 1996. pp. 1649–72.
  1. Lissauer H. Zwei Falle von Leukamie. Berl Klin Wochenschr 1865;2:403.
  2. Conrad ME. Treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1999;340:1043-5.
  3. Farreras P. Enfermedades de la sangre y órganos hematopoyéticos. En: Pedro Pons A. Patología y clínica médicas. 3 ed. Barcelona: Salvat; 1963. p. 192.

12. Aronson SM. Arsenic and old myths. R. I. Med J 1994;77:233–4.

  1. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24.
  1. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide and idarubicin-induced remission in relapsed acute promyelocytic leukemia: Clinicopathological and molecular features of a pilot study. Am J Hematol 2001;66:274-9.
  2. Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, et al. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: A bridgeto transplantation. Haematologica 2002;87:485-9.
  3. Lazo G, Kantarjian H, Estey E, Thomas D, O´Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia. Cancer 2003;97:2218-24.
  4. Hernández C, Machín S, Gómez M, Ramón L, Losada R, Agramonte O, et al. Uso del trióxido de arsénico (Arsenin ®) en el tratamiento de la leucemia promielocítica en recaída. Rev Cubana Hematol Inmunol Hemoter 2007; 23(1): [citado 05 Octubre 2007] Disponible en: <
  5. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Ying G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARdPML proteins. Blood 1996;88:1052-61.
  6. Miller W, Schipper H, Lee J, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893–903.
  7. Sanz M, Fenaux P, Lo Coco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005;90:1231-5.
  8. Zhou G, Zhao W, Wang Z, Chen S, Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Medicine. Disponible en: (citado 05 Octubre 2007).
  9. Joe Y, Jeong J, Yang S, Kang H, Motoyama N, Pandolfi P, et al. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem 2006:281:28764–71.

23. Kuschinsky G, Lüllmann H. Manual de farmacología. La Habana: Instituto del Libro; 1970.

24. Barbey J, Pezzullo J, Soignet S. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21:3609–15.

25. Westervelt P, Brown R, Adkins D, Khoury H, Curtin P, Hurd D, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001;98:266-71.

  1. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006;107:2627-32.
  2. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH. Treatment of acute promyelocytic leukemia without ATRA and/or chemotherapy. Ann Oncol 2006;17:131-4.
  3. Shen Z, Shi Z, Fang J, Gu B, Li J, Zhu Y, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101:5328-35.
  4. Estey E, Garcia- Manero G, Ferrajoli A, Faderl S, Verstovek S, Jones D, et al. Use of all-trans retinoic acid + arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 20061;107:3469-73.
  5. Rego EM, He LZ, Warrell RP, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc Natl Acad Sci USA. 2000;97:10173–8.

T-2

REFERENCIAS BIBLIOGRÁFICAS

  1. Stuart J, Stone PCW, Akinola NO. Monitoring the acute phase response to vaso-oclussive crisis in sickle cell disease. J Clin Pathol 1994;47:166-9.
  1. Singhal A, Dohrety JF, Raynes JG, McAdam KP, Thomas PW, Serjeant BE, et al. Is there an acute-phase response in steady state sickle cell disease? Lancet 1993;341:651-3.
  1. Hedo CC, Akenova YA, Okpala IE. Acute phase reactants and severity of homozygous sickle cell disease. J Inter Med 1993;233:467-70.
  1. Monnet D, Diallo I, Sangre A, Yapo AE. Clinical value of C-reactive protein, alpha 1-glycoprotein acid and transferrin assay in homozygous sickle cell disease. Bull Soc Pathol Exot 1993;86:282-5.
  1. Akinola NO, Stevens SME, Franklin IM. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol 1992;45:902-6.
  1. Ibe BO, Kurantsin-Mills J, Usha Raj J, Lessin LS. Plasma and urinary leukotrienes in homozygous sickle cell disease: possible role in the inflammatory process. Eur J Clin Invest 1994;24:57-64.
  1. Makis AC, Hatzimichael EC, Mavridis A, Bourantas KL. Alpha-2-macroglobulin and interleukin-6 levels in steady state sickle cell disease patients. Acta Haematol 2000;104:164-8.
  1. Bourantas KL, Dalekos GN, Makis AC, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 1998;61:49-54.
  1. Richardson P, Steingart R. Acute-phase response and sickle crisis. Lancet 1993;341:1349.
  1. Serjeant GR. Sickle cell disease. Lancet 1997;350:725-30.
  1. Forget BG. Anemia de células falciformes y hemoglobinopatías relacionadas. En: La Fayette R, Wyngaarden JB, Smith LH, edS. Tratado de medicina Interna. 19th ed. Ciudad México: Interamericana; 1994. pp. 1033-9.
  1. Mohamed AO, Hashim MS, Nilsson UR, Venge P. Increased in vivo activation of neutrophils and complement in sickle cell disease. Am J Trop Med Hyg 1993;49:799-803.
  1. Mann D, Shumacher HR. Pseudoseptic inflammatory knee effusion caused by phagocytosis of sickled erythrocytes after fracture into knee joint. Arthritis Rheum 1995;38:284-7.
  1. Humbert JR, Winsor EL, Githens JM, Schmitz JB. Neutrophil dysfunctions in sickle cell disease. Biomed Pharmacoter1990;44:153-8.
  1. Fadlon E, Vordermeier S, Pearson TC, Miresluis AR, Dumonde DC, Phillips J, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998;91:266-74.
  1. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, Mcmillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-oclusive sickle crisis. Blood 1998;92:2551-5.
  1. Chappey O, Wautier Pepin MP, Wautier JL. Adhesion of erythrocytes to endothelium in pathological situations: a review article. Nouv Rev Fr Hematol 1994;36:281-8.
  1. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997;99:2561-4.
  1. Daniels G. Functional aspects of red cell antigens. Transfus Med 1999;13:14-35.
  1. Montes RA, Eckman JR, Hsu LL, Wick TM. Sickle erythrocyte adherence to endothelium at low shear: role of shear stress in propagation of vaso-occlusion. Am J Hematol 2002;70:216-27.
  1. Kaul DK, Fabry ME, Nagel RL. The pathophysiology of vascular obstruction in the sickle syndromes. Blood Rev 1996;10:29-44.
  1. Walmet PS, Eckman JR, Wick TM. Inflammatory mediators promote strong sickle cell adherence to endothelium under venular flow conditions. Am J Hematol 2003;73:215-24.
  1. Moore CM, Ehlayel M, Leiva LE, Sorensen RU. New concepts in the immunology of sickle cell disease. Ann Allergy Asthma Immunol 1996;76:385-403.
  1. Kunz Mathews M, McLeod DS, Merges C, Cao J, Lutty GA. Neutrophils and leucocyte adhesion molecules in sickle cell retinopathy. Br J Ophthalmol 2002;86:684-90.
  1. BallasSK, Mohandas N. Pathophysiology of vaso-oclusion. Hematol Oncol Clin North Am 1996;10:1221-38.
  1. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol 1999;66:411-5.
  1. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: a potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000;96:2451-9.
  1. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001;97:1937-41.
  1. Duits AJ, Pieters RC, Saleh AW, van Rosmalen E, Katerberg H, Berend K, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 1996;81:96-8.
  1. Schnog JB, Rojer RA, Mac Gillavry MR, Ten Cate H, Brandjes DP, Duits AJ. Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol 2003;82:109-13.
  1. Duits AJ, Rojer RA, van Endt T, MacGillavry MR, ten Cate H, Brandjes DP, et al. Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease. Ann Hematol 2003;82:171-4.
  1. Okpala I, Daniel Y, Haynes R, Odoemene D, Goldman J. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol 2002;69:135-44.
  1. Garraty G, Telen MJ, Petz LD. Red cell antigens as functional molecules and obstacles to transfusion. Hematology 2002;445-62.
  1. Parsons SF, Spring FA, Chasis JA, Anstee DJ. Erythroid cell adhesion molecules Lutheran and LW in health and disease. Baillieres Best Pract Res Clin Haematol 1999;12:729-45.
  1. Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med 2001;20:47-72.
  1. Benkerrou M, Delarche C, Brahimi L, Fay M, Vilmer E, Elion J, et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002;99:2297-303.
  1. Donadi EA, Falcao RP. Are the changes of lymphocytes subsets in sickle cell anemia due to the loss of splenic function? Acta Haematol 1988;80:91-4.
  1. Rivero R, Macías C, del Valle L, Lorigados L, Inclán G, Espinosa E, et al. Inmunodeficiencia celular asociada a la anemia drepanocítica. Rev Cub Hematol Inmunol Hemoter 1991;7:80-7.
  1. Glassman AB. Lymphocyte blast transformation and peripheral lymphocyte percentages in patients with sickle cell disease. Am Clin Lab Sci 1980;10:9-17.
  1. Hedo C, Akenova Y, Okpala I, Salimonu L. Serum immunoglobulin (G, A and M) classes and IgG subclasses in sickle cell anaemia. APMIS 1993;101:353-7.
  1. Kaplan J, Sarmaik SH, Levy J. Transfusion induce immunologic abnormalities not related to AIDS virus. N Engl J Med 1985;313:1227.
  1. Falcao RP, Donadi EA. Infection and immunity in sickle cell disease. AMB Rev Assoc Med Bras 1989;35:70-4.
  1. González-Amaro R, Sánchez- Madrid F. Cell Adhesion Molecules: Selectins and Integrins. Crit Rev Immunol 1999;19:389-429.
  1. Rivero RA, Aranda RE, Cruz C, Lorigados LC, Hernández P. Subpoblaciones de linfocitos T en la anemia drepanocítica. Rev Cub Hematol Inmunol Hemot 1986;2:90-92.
  1. Rivero R, Macías C, del Valle L, Lorigados L, Inclán G, Aranda RE, et al. Alteraciones inmunológicas en la anemia drepanocítica. Sangre 1991;36:15-20.
  1. Rivero R, Macías C, del Valle L, Lorigados L, Inclán G, Espinosa E, et al. Inmunodeficiencia celular asociada a la anemia drepanocítica. Rev Cub Hematol Inmunol Hemoter 1991;7:80-7.
  1. Von Andrian UH, Mackay CR. Advances in Immunology:T Cell Function and Migration. Two sides of the same coin. N Engl J Med 2000;343:1020-34.
  1. Bianchi G, Sironi M, Ghibaudi E, Selvaggini C, Elices M, Allavena P, et al. Migration of natural killer cells across endothelial cell monolayers. J Immunol 1993;151:5135-44.
  1. Allavena P, Bianchi G, Paganin C, Giardina G, Mantovani A. Regulation of adhesion and transendothelial migration of natural killer cells. Nat Immun 1996-97;15:107-16.

50. Macías C, Ballester JM, Hernández P. Expression and functional activity of the very late activation antigen-4 molecule on human natural killer cells in different states of activation. Immunology 2000;100:77-83.

  1. Reiner Z, Tedeschi-Reiner E. New information on the pathophysiology of atherosclerosis. Lijec Vjesn 2001;123:26-31.
  1. Dover GJ. SS disease is not a single gene disorder. Blood 2002;100:4255-8.
  1. Taylor VI JG, Tang DC, Savage ShA, Leitman SF, Heller SI, Serjeant GR et al. Variants in the VCAM-1 gene an drisk for symptomatic stroke in sickle cell disease. Blood 2002;100:4303-9.
  1. Telen MJ. Red blood cell surface adhesion molecules: their possible roles in normal human physiology and disease. Semin Hematol 2000;37:130-42.
  1. Belfield H, Green CA, James J, Forbes B, Massey E, Hones J, et al. Elevated expression of Lutheran and LW glycoproteins on red cell and erythroid precursors in haemoglobin SC disease. Transfus Med 2002;12:20.
  1. Lutty GA, Taomoto M, Cao J, McLeod DS, Vanderslice P, McIntyre BW, et al. Inhibition of TNF induced sickle RBC retention in retina by a VLA4 antagonist. Invest Ophthalmlo Vis Sci 2001;42:1349-55.
  1. Yamaja BN, Surekha S, Kolkarni M, Stuart J. Role of erythrocyte phosphatidylserine in sickle red cell endothelial adhesion. Blood 2002;99:1564-71.
  1. Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. Drugs 2002; 62:1143-72.
  1. Mankad VN. Exciting new treatment approaches for pathophysiologic mechanisms of sickle cell disease. Pediatr Pathol Mol Med 2001;20:1-13.
  1. Rezaei Kalantari H. How I treat....sickle cell anemia: current therapies. Rev Med Liege 2001;56:671-5.
  1. Saleh AW, Hillen HF. Pharmacological induction of foetal haemoglobin synthesis in sickle-cell disease. Neth J Med 1997;51:619-78.
  1. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol 1997;34:42-7.
  1. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol 1999;102:31-7.
  1. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89:2554-9.
  1. Benkerrou M, Delarche C, Brahimi L, Fay M, Vilmer E, Elion J, et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002;99:2297-303.
  1. Schnog JJ, Lard LR, Rojer RA, Van der Dijs FP, Muskiet FA, Duits AJ. New concepts in assessing sickle cell disease severity. Am J Haematol 1998;58:61-6.
  1. Vichisky E. New therapies in sickle cell disease. Lancet 2002;360:629-31.
  1. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002;100:3790-6.
  1. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001;97:1973-41.
  1. Telen MJ. Red blood cell surface adhesion molecules: their possible roles in normal human physiology and disease. Semin Hematol 2000;37:130-42.

T-3

REFERENCIAS BIBLIOGRÁFICAS

  1. Mollison PI, Emgelfriet CP, Contreras P. Blood Transfusion. En: Clinical Medicine. 9 ed. Oxford: Blackwell Scientific Publications; 1993.
  1. Salmon C. Les Groupes sanguins ou I´ecriture des Genes. Paris: Editorial Masson; 1997.
  1. Clausen H, Bennett EP, Grunnet N. Molecular genetics of ABO. Vox Sang 1994;78(Suppl 2):91–103.
  1. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Moullac-Vaidye B, Clement M. ABH and Lewis histo-blood group antigens in cancer. APMIS 2001;109:9–31.
  1. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999;1473:247–66.
  1. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002; 99:10231–3.
  1. Gao S, Worm J, Guldberg P, Eiberg H, Krogdahl A, Liu CJ. Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer (2004b);109:230–7.
  1. Mandel U, Orntoft TF, Holmes EH, Sorensen H, Clausen H, Hakomori S, et al. Lewis blood group antigens in salivary glands and stratified epithelium: lack of regulation of Lewis antigen expression in ductal and buccal mucosal lining epithelia. Vox Sang 1991;61:205–4.
  1. Hakomori S, Handa K. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett 2002;531:88–92.
  1. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000; 108:1–28.
  1. Walkers J. American Association of Blood Banks. Manual técnico. 13 ed. Asociación Argentina de Hemoterapia e Inmunohematología. Buenos Aires; 2002.
  1. Strauchen JA, Bergman SM, Hanson TA. Expression of A and B Tissue Isoantigens in benign and malignant lesions of the Breast. Cancer 1980;45:2149–61.
  1. Strauchen JA, Bergman SM, Hanson TAM (1998). Expression of A and B Tissue Isoantigens in benign and malignant lesions of the Breast. Cancer 45:2149–55.
  1. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000;108:1–28.
  1. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999;1473:247–66.
  1. Solís E, Provenzal O, Valverde J, Biondi C, Foresto P, Muller R, et al. Comparative study of the ABH antegenic expression between urothelium and buccal desquamation cells in patients with bladder carcinoma. Acta Urol Itál 1997;1:187-8.
  1. Foresto P, Biondi C, Racca L, Brufman A, Yaber F, Solís E, Provenzal O, Valverde J. Glicosilación anormal de antígenos ABH solubles en patologías tumorales del tracto urinario. Arch Esp Urol 2000;53:196-9.
  1. Santos-García A, Abad-Hernández MM, Fonseca-Sánchez E, Julián-Gonzalez R, Galindo-Villardón P, Cruz-Hernández J. E-cadherin, laminin and collagen IV expression in the evolution from dysplasia to oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2006;11:E100-5.
  1. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000; 108:1–28.

T-4

REFERENCIAS BIBLIOGRÁFICAS

  1. Greer JP, Foerster J, Lukens JN, Rodgers GM, Parackevas F, Glader B. Wintrobe´s Clinical Hematology. 11 ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
  1. National Institute of Health. National Heart, Lung and Blood Institute Division of Blood diseases and resources. The management of sickle cell disease. NIH publication. No. 02-2117. 4 ed. Jun 2002.
  1. The SickleCellInformationCenter. Services NIH Guidelines. Management of sickle cell disease. Chapter 13. Stroke and central nervous system disease. Atlanta, GeorgiaUSA. Updated November 5, 2002.
  1. Ohene-Frempong K, Weiner SJ, Sleeper LA. and the Cooperative Study of Sickle Cell Disease. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998;91:288-94.
  1. Seibert JJ, Miller SF, Kirby RS, Becton DL, James CA, Glasier CM, et al. Cerebrovascular disease in symptomatic and asymptomatic patients with sickle cell anemia: Screening with duplex transcranial doppler US-correlation with MR imaging and MR angiography. Radiology 1993;189:457-82.
  1. Buchanan GR, DeBraun MR, Quinn CT, Steinberg MH. Sickle cell disease. Hematology. ASH 2004.
  1. D'Asseler YM, Koole M, Lemahieu I, Achten E, Boon P, De Deyn PP. Recent and future evolutions in Neuro SPECT with particular emphasis on the synergistic use and fusion of imaging modalities. Acta Neurol Belg 1997;97:154-9.
  1. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, et al. The use of transcranial ultrasonography to predict stroke in sickle-cell disease. N Engl J Med 1992;326:605-12.
  1. Adams RJ, Ohene-Frempong K, Wanf W. Sickle cell and the brain. Hematology. ASH 2001:45.
  1. Moser FG, Miller ST, Bello JA. The spectrum of brain MR abnormalities in sickle cell disease: a report from the cooperative study of sickle cell disease. Am JNeuroradiol1996;17:965-72.
  1. Prengler M, Pavlakis SG, Boyd S, Connelly A, Calammante F, Chong WK. Sickle cell disease and electroencephalogram hyperventilation. Ann Neurol 2006;59:214-5.
  1. Ringelstein EB. Transcranial Doppler sonography. En: Poek K, Ringelstein EB, Hacke W. Berlin: Springer-Verlag; 1987. p. 3-28.
  1. Mohr JP. Sickle cell anemia, stroke and transcranial doppler studies. N Eng J Med 1992;326:637-9.
  1. Adams RJ, Nichols FT, Aaslid R, McKie VC, McKie K, Carl E, et al. Cerebral vessels stenosis in sickle cell disease: criteria for detection by transcraneal doppler. Amer J Pediatr Hematol Oncol 1990;12:277-82.
  1. Numaguchi Y, Haller JS, Humbert JR, Robinson AE, Lindstrom WW, Gruenauer LM. Cerebral blood flow mapping using stable Xenon-enhanced CT in sickle cell cerebrovascular disease. Neuroradiology 1990;32:289-95.
  1. Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology 1988;38:1012-7.
  1. Serjeant GR. Sickle cell disease. Oxford: OxfordUniversity Press; 1995. p 233-46.
  1. Claster S, Vichinsky EP. Managing sickle cell disease. Brit Med J 2003;327:1151-5.

T-5

REFERENCIAS BIBLIOGRÁFICAS

  1. Siminovitch L, McCullouch, Till JE. The distribution of colony-forming cells among spleen colonies. J Cell Comp Physiol 1963;62:327-36.
  1. Clift RA, Thomas ED. Seattle Marrow Transplant Team. Follow-up 26 years after treatment for acute myelogenous leukemia. N Engl J Med 2004;351:2456-7.
  1. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923-30.
  1. Benito AJ, Diaz MA, Gonzalez-Vicent M, Sevilla J, Madero L. Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplant 2004;33:675-90.
  1. Warwick R, Armitage S. Cord blood banking. Best Pract Res Clin Obstet Gynaecol 2004;18:995-1011.
  1. Watt SM, Contreras M. Stem Cell medicine: Umbilical cord blood and its stem cell potential. Semin Fetal Neona Med 2005;10:209-20.
  1. Broxmeyer HE. Cord Blood: biology, immunology, banking and clinical transplantation. Bethesda, MD: AABB Press. 2004.
  1. Zhang Y, Chai C, Jiang XS, Teoh SH, Leong KW. Co-culture of umbilical cord blood CD34+ cells with Human Mesenchymal Stem Cells. Tissue Eng 2006;12:2161-70.
  1. Devine SM, Lazarus HM, Emerson SG. Clinical application of hematopoietic progenitor cell expansion: current status and future prospects. Bone Marrow Transplant 2003;31:241-52.
  1. Heike T, Nakahata T. Ex vivo expansion to hematopoietic stem cells by cytokines. Biochim Biophys Acta 2002;1592:313-21.
  1. Kohler T, Plettig R, Wetzstein W, Schaffer B, Ordemann R, Nagels HO, et al. Defining optimum conditions for the ex vivo expansion of human umbilical cord blood cells. Influences of progenitor enrichment, interference with feeder layers, early-acting cytokines and agitation of culture vessels. Stem Cells 1999;17:19-24.
  1. Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, Kowalska MA, et al. Numerous growth factors, cytokines and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001;97:3075-85.
  1. Nicola NA, Greenhalgh CJ. The suppressors of cytokine signaling (SOCS) proteins: Important feedback inhibitors of cytokine action. Exp Hematol 2000; 28:1105-12.
  1. Rosmarin AG, Yang Z, Resendes K. Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation and leukemogenesis. Exp Hematol 2005 33:131-43.
  1. Alenzi FQB, Marley SB, Lewis JL, Chandrashekran A, Warrwns AN, Goldman JM et al. A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. Exp Hematol 2002;30:1428-35.
  1. Maurillo L, Del Poeta G, Venditti A, Bucciana F, Battaglia A, Santinelli S, et al. Quantitative Analysis of Fas and Bcl-2 expression in haematopoietic precursors. Haematologica 2001; 86:237-43.
  1. Ross J, Li L. Recent advances in understanding extrinsic control of hematopoietic stem cell fate. Curr Opin Hematol 2006;13:237-42.
  1. Francis K, Ramakrishna R, Holloway W, Palsson BQ. Two new pseudopod morphologies displayed by the human hematopoietic KG1a progenitor cell line and by primary human CD34+ cells. Blood 1998; 92:3616-23.
  1. Frimberger AE, McAuliffe CI, Werme KA, Tuft RA, Fogarty KE, Benoit BO, et al. The fleet feet of haematopoietic stem cells: rapid motility, interaction and proteopodia. Br J Haematol 2001;112:644-54.
  1. Ho AD. Kinetics and symmetry of divisions of hematopoietic stem cells. Exp Hematol 2005; 33:1-8.
  1. Yoo ES, Lee KE, Seo JW, Yoo EH, Lee MA, Im SA, et al. Adherent Cells Generated During Long-Term Culture of Human Umbilical Cord Blood CD34+ Cells Have Characteristics of Endothelial Cells and Beneficial Effect on Cord Blood Ex Vivo Expansion. Stem Cells 2003; 21: 228-35.
  1. Opie TM, Shields LE, Andrews RG. Cell surface antigen expression in early and term gestation fetal hematopoietic progenitor cells. Stem Cells 1998; 16:343-8.
  1. D’Arena G, Musto P, Cascavilla N, DiGiorgo G, Zendoli F, Carotenuto M. Human umbilical cord blood: immunophenotypic heterogeneity of CD34+ hematopoietic progenitor cells. Haematologica 1996;81:404-9.
  1. Peters R, Leyvraz S, Perey L. Apoptotic regulation in Primitive Hematopoietic Precursors. Blood 1998; 92:2041-52.
  1. Madlambayan GJ, Rogers I, Kirouac DC, Yamanaka N, Mazurier F, Doedens M et al. Dynamic changes in cellular and microenvironment composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. Exp Hematol 2000;28:1297-305.
  1. Kirouac DC, Zandstra PW. Understanding cellular networks to improve hematopoietic stem cell expansion cultures. Current Opin Biotechnol 2006; 17:538-47.
  1. Lin KK, Goodell MA. Purification of hematopoietic stem cells using the side population. Methd Enzymol 2006; 420:255-64.

T-6